Angelini Pharma, an Italian pharmaceutical company, has completed the acquisition of Catalyst Pharmaceuticals, a U.S. rare-disease drug maker, in a $4.1 billion deal involving Italian state lender CDP.
Deal Details
The acquisition gives Angelini full ownership of Catalyst’s portfolio of rare disease treatments and its commercial operations in the U.S., creating a new platform for growth in neurological and rare disorders. Angelini Pharma paid $31.50 in cash for each Catalyst share.
The deal was financed by a pool of 14 Italian and international financial institutions, led by France’s BNP Paribas. CDP Equity, the investment arm of CDP, invested around €1 billion to buy 23.5% of Angelini Pharma through a capital hike to help fund the transaction.
Italy will remain a strategic production and scientific hub for Angelini’s operations. The deal is a “decisive step” in transforming Angelini into a global pharmaceutical player, said its Chief Executive Sergio Marullo di Codojanni.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
